Last reviewed · How we verify
NCT05207462
A Feasibility Study of Intensive Treatment With Prolonged Exposure
NA trial testing Intensive treatment with prolonged exposure in Post Traumatic Stress Disorder in 33 participants. Completed in 22 July 2023.
22 July 2023
Quick facts
| Lead sponsor | Karolinska Institutet |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 24 January 2022 |
| Primary completion | 22 July 2023 |
| Estimated completion | 22 July 2023 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Intensive treatment with prolonged exposure
Conditions studied
- Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →
Sponsor
Karolinska Institutet
Who can join
18 and older, any sex, with Post Traumatic Stress Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective with this study is to investigate the feasibility and acceptability of intensive treatment with prolonged exposure (I-PE) in regular Swedish psychiatric care. The secondary objective is to investigate preliminary effects of i-PE in terms of reducing symptoms of post-traumatic stress, depression and increase quality of life.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Enduring intensity for healing: the patient perspective of intensive outpatient treatment for PTSD.
Bragesjö M, Ivanov VZ, Farman S, Panagiotidou M, et al · · 2025 · cited 1× · PMID 40326477 · DOI 10.1080/20008066.2025.2497160 -
Feasibility of intensive prolonged exposure for PTSD: a pragmatic pilot study in Swedish public outpatient psychiatry.
Jamil S, Rück C, Bragesjö M. · · 2026 · PMID 41593574 · DOI 10.1186/s12888-026-07836-1
Verify or expand the search:
- PubMed search for NCT05207462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Intensive treatment with prolonged exposure
Trials testing the same drug.
- NCT05934175 — Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder · NA · recruiting
Other recruiting trials for Post Traumatic Stress Disorder
Currently open trials in the same condition.
- NCT07485231 — Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD · NA · recruiting
- NCT07316088 — Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms · Phase 2 · recruiting
- NCT07227337 — Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study · NA · recruiting
- NCT06988787 — Multifaceted Intervention to Restore Resilience and Overcome Risk · NA · recruiting
- NCT06740487 — Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder · NA · recruiting
Other Karolinska Institutet trials
Trials by the same sponsor.
- NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
- NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
- NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
- NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
- NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05207462 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
- Last refreshed: 7 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05207462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing